| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d7c6bbb3923cc2ccdd1f4322952572c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6793746879e7d0b5b283b6acdf99fc38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_230d0b602db14637ce60ba11fe71d33c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1098 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10 |
| filingDate |
2018-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04b0ffee2db105d08853bb90d10de744
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2e33d9ebd7ccb9b94d708ac8f080b19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c06cf21a351689b99f6f957367bda78 |
| publicationDate |
2019-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019298982-A1 |
| titleOfInvention |
Treating Tumors Using TTFields Combined with a PARP Inhibitor |
| abstract |
Tumor-Treating Fields elicit a conditional vulnerability to PARP inhibitors (e.g., Olaparib) in certain cancer cells such as non-small cell lung cancer (NSCLC) cell lines. This conditional vulnerability is exploited in a method of killing cancer cells that comprises delivering a PARP inhibitor to the cancer cells and applying an alternating 80-300 kHz electric field to the cancer cells. At least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. In some embodiments, an additional step of treating the cancer cells with a radiation therapy is added to the method. In some embodiments, the frequency of the alternating electric field is between 100 and 200 kHz. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11529511-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11351349-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11103698-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022192719-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021194919-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11650277-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10967167-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11179322-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400269-B2 |
| priorityDate |
2018-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |